

CORRECTED
VERSION*CORRECTED
VERSION**

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/12, C07K 14/705, C12Q 1/68, G01N 33/53, C07K 16/28, A61K 38/17, 31/70, 39/00, 35/12, 39/395, 48/00		A3	(11) International Publication Number: WO 99/04265
			(43) International Publication Date: 28 January 1999 (28.01.99)
(21) International Application Number: PCT/US98/14679			
(22) International Filing Date: 15 July 1998 (15.07.98)			
(30) Priority Data:			
08/896,164	17 July 1997 (17.07.97)	US	
60/061,599	10 October 1997 (10.10.97)	US	
60/061,765	10 October 1997 (10.10.97)	US	
08/948,705	10 October 1997 (10.10.97)	US	
9721697.2	11 October 1997 (11.10.97)	GB	
09/102,322	22 June 1998 (22.06.98)	US	
(71) Applicant (for all designated States except US): LUDWIG INSTITUTE FOR CANCER RESEARCH [CH/US]; 605 Third Avenue, New York, NY 10158 (US).			
(72) Inventors; and			
(75) Inventors/Applicants (for US only): OLD, Lloyd, J. [US/US]; 1345 Avenue of the Americas, New York, NY 10105 (US). SCANLAN, Matthew, J. [US/US]; 1275 York Avenue, New York, NY 10021 (US). STOCKERT, Elisabeth [US/US]; 1275 York Avenue, New York, NY 10021 (US). GURE, Ali [TR/US]; 1275 York Avenue, New York, NY 10021 (US). CHEN, Yao-Tseng [-/US]; The New York Hospi- tal-Cornell Medical Center, Dept. of Pathology, 525 East 68th Street, New York, NY 10021 (US). GOUT, Ivan			
		[UA/GB]; 91 Riding House Street, London W1P 8BT (GB). O'HARE, Michael [GB/GB]; 91 Riding House Street, Lon- don W1P 8BT (GB). OBATA, Yuichi [JP/JP]; Chikusa-Ku, Nagoya 464 (JP). PFREUNDSCUH, Michael [DE/DE]; Innere Medizin 1, D-66421 Homburg/Saar (DE). TURECI, Ozlem [DE/DE]; Innere Medizin 1, D-66421 Homburg/Saar (DE). SAHIN, Ugur [TR/DE]; Innere Medizin 1, D-66421 Homburg/Saar (DE).	
		(74) Agent: VAN AMSTERDAM, John, R.; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210 (US).	
		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
		Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	
		(88) Date of publication of the international search report: 26 August 1999 (26.08.99)	
(54) Title: CANCER ASSOCIATED NUCLEIC ACIDS AND POLYPEPTIDES			
(57) Abstract			
<p>Tumor cell-specific antigens from melanoma cells have previously been identified using autologous cytolytic T cells clones from the patient, but the same approach did not work well with other tumour types. Here, screening of such antigens was successfully performed using antisera from the patient. Provided are several tumor cell-specific antigens, nucleic acids encoding them, antibodies and CTL's directed against these antigens, antigenic fragments diagnostic kits, etc.</p>			

*(Referred to in PCT Gazette No. 19/1999, Section II)

**(Referred to in PCT Gazette No. 27/1999, Section II)

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

INTERNATIONAL SEARCH REPORT

International Application No

PCT/JP 98/14679

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/12 C07K14/705 C12Q1/68 G01N33/53 C07K16/28
 A61K38/17 A61K31/70 A61K39/00 A61K35/12 A61K39/395
 A61K48/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07K A61K G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>WO 97 17470 A (HOLLAND JAMES F) 15 May 1997</p> <p>Also against claims 82-84,116,117see whole document, particularly the claims --- -/--</p>	<p>1,2, 4-10,18, 21-23, 27,28, 31,32, 40,42, 44,45, 48-51, 58-60, 67-70, 76-79</p>



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- * & * document member of the same patent family

Date of the actual completion of the international search

3 June 1999

Date of mailing of the international search report

29.06.1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Smalt, R

INTERNATIONAL SEARCH REPORT

International Application No

PCT/JP 98/14679

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GB 2 273 099 A (ASTA MEDICA AG) 8 June 1994 Also against claims 108,109,116,117. See whole document, particularly the claims and examples. ---	1,2, 4-10,31, 32,40, 42,43, 49,50, 58-60, 67,69, 71,72, 74-79, 82-84, 99-104
X	WO 97 17441 A (KISHIMURA MASAOKI ;OSAKADA FUMIO (JP); OSAKI SHOICHI (JP); NAKAO K) 15 May 1997 see the whole document -& EP 0 869 176 A (KANEKA CORPORATION, OSAKA, JAPAN) 7 October 1998 Also against claims 68-72,74,76,77,82,116,117 see claims 10 12; examples 2,5 ---	1,2,4-8, 13,18, 21,22, 24, 27-29, 31,32, 35,40, 42,44, 45, 47-50, 54,59, 60,63,67
X	WO 97 02362 A (FOX CHASE CANCER CENTER) 23 January 1997 see the whole document, particularly the claims and seq. 1 and 2. Also against claims 70-72,74,76-80,82-85,88,89,99-104,108-111, 116,117. see page 18, line 20 - page 22, line 33 --- -/--	1,2, 4-10,15, 18, 21-24, 27-29, 31,32, 37,40, 42-45, 47-50, 56, 58-60, 65,67

INTERNATIONAL SEARCH REPORT

International Application No

PCT, 98/14679

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>VAUGHAN, J.H. ET AL.: "Epstein-Barr virus-induced autoimmune responses." JOURNAL OF CLINICAL INVESTIGATION, vol. 95, no. 3, March 1995, pages 1306-15, XP002103180</p> <p>see the whole document -& DATABASE EMBL - EMHUM1 Entry HSIIGGAUA, Acc.no. L38696, 17 February 1995 VAUGHAN, J.H. ET AL.: "Homo sapiens autoantigen p542 mRNA, complete cds." XP002103198 see the whole document</p> <p>---</p>	<p>1,2,18, 21,22, 24, 27-29, 31,35, 40,44, 45, 47-50, 54,59, 60,63, 67-72, 74-80,82</p>
X	<p>MASHIMO, J. ET AL.: "Decrease in the expression of a novel TGF beta1-inducible and ras-recision gene, TSC-36, in human cancer cells." CANCER LETTERS, vol. 113, March 1997, pages 213-9, XP002104545 see abstract</p> <p>---</p>	<p>1,2, 4-10,13</p>
X	<p>MACHIELS, B.M. ET AL.: "Nuclear lamin expression in normal testis and testicular germ cell tumours of adolescents and adults." JOURNAL OF PATHOLOGY, vol. 182, no. 2, June 1997, pages 197-204, XP002104546 see abstract see page 198, left-hand column, paragraph 2</p> <p>---</p>	<p>1,2, 4-10,15, 31,32, 37,40, 42,116, 117</p>
X	<p>COATES, P.J. ET AL.: "Identification of the antigen recognized by the monoclonal antibody BU31 as lamins A and C" JOURNAL OF PATHOLOGY, vol. 178, no. 1, January 1996, pages 21-9, XP002104547 see abstract</p> <p>---</p> <p>-/--</p>	<p>1,2, 4-10,15, 31,32, 37,40, 42,116, 117</p>

INTERNATIONAL SEARCH REPORT

International Application No

PC1, JS 98/14679

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>ZWIJSEN, A. ET AL.: "Characterization of a rat C6 glioma-secreted follistatin-related protein (FRP); cloning and sequencing of the human homologue." EUROPEAN JOURNAL OF BIOCHEMISTRY, vol. 225, no. 3, November 1994, pages 937-46, XP002103181</p> <p>see page 945, right-hand column, paragraph 2-4; figure 3</p>	<p>18,21, 22,24, 27,28, 44,45, 47-50, 54,59, 60,63, 67-72, 74-80,82</p>
X	<p>MINEGISHI, M. ET AL.: "Structure and function of Cas-L, a 105 kD Crk-associated substructure-related protein that is involved in beta-1 integrin-mediated signaling in lymphocytes." JOURNAL OF EXPERIMENTAL MEDICINE, vol. 184, no. 4, 1 October 1996, pages 1365-75, XP002103183</p> <p>also against claims 116 and 117 see figure 4</p>	<p>18, 21-23, 27-29, 31,32, 37,40, 44,45, 47-50, 56, 58-60, 65, 67-72, 74-80, 82-84</p>
X	<p>JIN, Y-J. ET AL.: "The 25-kDa FK506-binding protein is localized in the nucleus and associated with casein kinase II and nucleolin." PROC.NAT'L.ACAD.SCI.USA, vol. 90, August 1993, pages 7769-73, XP002104548 see the whole document</p>	<p>31,32, 35,40, 116,117</p>
X	<p>WO 96 15149 A (UNIV WASHINGTON) 23 May 1996 see page 23, line 2 - line 3</p>	<p>31,32, 37,40</p>
X	<p>WO 97 21729 A (SLOAN KETTERING INST CANCER) 19 June 1997</p> <p>see page 3, line 24 - line 29 see page 6, line 27 - line 29; figure 3 see page 27, line 15 see page 28, line 27 - line 28</p>	<p>31,32, 37, 40-42, 116,117</p>
	<p>---</p> <p>-/--</p>	

INTERNATIONAL SEARCH REPORT

International Application No

PCT, J 98/14679

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>NOCE, T. ET AL.: "Expresson of a mouse zinc finger protein gene in both spermatocytes and oocytes during meiosis." DEVELOPMENTAL BIOLOGY, vol. 153, no. 2, October 1992, pages 356-67, XP002104549 see abstract; figures 1,5-7 -& DATABASE EMBL - EMROD Entry MMZFP51, Acc.no. D10630, 8 November 1992 NOCE, T. ET AL.: "Mouse mRNA for zinc finger protein, complete cds." XP002104555 see the whole document</p> <p>---</p>	<p>31,32, 37,40, 42, 67-70, 116,117</p>
X	<p>ONO M ET AL: "NUCLEOTIDE SEQUENCE OF HUMAN ENDOGENOUS RETROVIRUS GENOME RELATED TO THE MOUSE MAMMARY TUMOR VIRUS GENOME" JOURNAL OF VIROLOGY, vol. 60, no. 2, 1 November 1986, pages 589-598, XP000673638 see page 597, left-hand column, paragraph 5 - right-hand column, paragraph 1; figure 1</p> <p>---</p>	<p>44,45, 47,48, 59,60, 67-72,74</p>
X	<p>DATABASE EMBL - EMBEST16 Entry HSC9958, Acc.no. C15995, 29 September 1996 FUJIWARA, T. ET AL.: "Human fetal brain cDNA 5'-end GEN-421G02." XP002103191 see the whole document</p> <p>---</p>	<p>44,59, 60,63, 67-70</p>
X	<p>DATABASE EMBL - EMBEST13 Entry HS570350, Acc.no. W45570, 27 May 1996 HILLIER, L. ET AL.: "zc26f08.s1 Soares senescent fibroblasts NbHSF Homo sapiens cDNA clone 323463 3'" XP002103192 see the whole document</p> <p>---</p>	<p>44,59, 60,63, 67-70</p>
X	<p>DATABASE EMBL - EMBEST15 Entry HSA07407, Acc.no. AA007407, 28 July 1996 HILLIER, L. ET AL.: "zh97b08.r1 Soares fetal liver spleen 1NFLS S1 Homo sapiens cDNA clone 429207 5'" XP002103193 see the whole document</p> <p>---</p> <p style="text-align: center;">-/--</p>	<p>44,59, 60,63, 67-70</p>

INTERNATIONAL SEARCH REPORT

International Application No

PCT, 98/14679

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	HUNG, D.T. ET AL.: "cDNA cloning of a human 25 kDa FK506 and rapamycin binding protein." BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 184, no. 2, 30 April 1992, pages 733-8, XP002103178 see figure 2	44,59, 60,63, 67-70
X	--- JIN, Y-J. ET AL.: "Molecular cloning of a 25-kDa high affinity rapamycin binding protein, FKBP25." JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 267, no. 16, 5 June 1992, pages 10942-5, XP002104550 see figure 3	44, 47-50, 54,59, 60,63, 67-72, 75,83,84
X	--- MACLEOD, A.R. ET AL.: "A muscle-type tropomyosin in human fibroblasts: evidence for expression by an alternative RNA splicing mechanism." PROC.NAT'L.ACAD.SCI.USA, vol. 82, December 1985, pages 7835-9, XP002103179 see figures 2,3	44,59, 60,63, 67-70
X	--- DATABASE EMBL - EMEST20 Entry/Acc.no. T09468, 8 August 1993 ADAMS, M.D. ET AL.: "EST07361 Homo sapiens cDNA clone H18BU63 5' end." XP002103195 see the whole document -& ADAMS, M.D. ET AL.: "Rapid DNA sequencing (expressed sequence tags) from a directionally cloned human infant brain cDNA library." NATURE GENETICS, vol. 4, 1993, pages 373-380, XP000574910 see the whole document	44,45, 67,70
X	--- DATABASE EMBL - EMEST17 Entry HSZZ32361, Acc.no. AA327309, 18 April 1997 ADAMS, M.D. ET AL.: "EST30621 Colon I Homo sapiens cDNA 5' end." XP002103199 see the whole document -& ADAMS, M.D. ET AL.: "Initial assessment of human gene diversity and expression patterns based upon 83 million nucleotides of cDNA sequence." NATURE, vol. 377, 1995, pages 3-17, XP002042918 see the whole document ---	44,45, 60,62, 67,70
	--- -/--	

INTERNATIONAL SEARCH REPORT

International Application No

PCT, 98/14679

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE EMBL - EMBEST15 Entry HSAA33416, Acc.no. AA133416, 6 December 1996 HILLIER, L. ET AL.: "zk96e08.r1 Soares pregnant uterus NbHPU Homo sapiens cDNA clone 490694 5'." XP002103196 see the whole document</p> <p>---</p>	44,45, 67,70
X	<p>DATABASE EMBL - EMBEST11 Entry HS1282878, Acc.no. AA487071, 28 June 1997 HILLIER, L. ET AL.: "ab18f11.s1 Stratagene lung (#937210) Homo sapiens cDNA clone 841197 3' similar to contains Alu repetitive element." XP002103197 see the whole document</p> <p>---</p>	44,45, 67,70
X	<p>DATABASE EMBL - EMBEST15 Entry HSAA21198, entry AA121198, 21 November 1996 HILLIER, L. ET AL.: "z188g08.r1 Stratagene colon (#937204) Homo sapiens cDNA clone 511742 5'." XP002103200 see the whole document</p> <p>---</p>	44,45, 60,62, 67,70
X	<p>DATABASE EMBL - EMBEST15 Entry HSAA21174, Acc.no. AA121174, 21 November 1996 HILLIER, L. ET AL.: "z188g08.s1 Stratagene colon (#937204) Homo sapiens cDNA clone 511742 3'." XP002103202 see the whole document</p> <p>---</p>	44,45, 60,62, 67,70
X	<p>DATABASE EMBL - EMBEST17 Entry HSW22160, Acc.no. W22160, 9 May 1996 NATHANS, J.: "63A6 Human retina cDNA Tsp509I-cleaved sublibrary Homo sapiens cDNA not directional." XP002103201 see the whole document</p> <p>---</p>	44,45, 60,62, 67,70
X	<p>DATABASE EMBL - EMBEST15 Entry HSA29201, Acc.no. AA029201, 20 August 1996 HILLIER, L. ET AL.: "zk12f08.s1 Soares pregnant uterus NbHPU Homo sapiens cDNA clone 470343 3'." XP002103203 see the whole document</p> <p>---</p>	44,45, 60,62, 67,70

	-/--	

INTERNATIONAL SEARCH REPORT

International Application No

PCT, 98/14679

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE EMBL - EMBEST17 Entry HSW29097, Acc.no. W29097, 14 May 1996 NATHANS, J.: "56d11 Human retina cDNA randomly primed sublibrary Homo sapiens cDNA." XP002103204 see the whole document</p> <p>---</p>	44,45, 60,62, 67,70
X	<p>MIKI Y ET AL: "A STRONG CANDIDATE FOR THE BREAST AND OVARIAN CANCER SUSCEPTIBILITY GENE BRCA1" SCIENCE, vol. 266, no. 12, 7 October 1994, pages 66-71, XP000202410 see the whole document -& DATABASE EMBL - EMBEST5 Entry/Acc.no. AF039241, 17 January 1998 MIKI, Y. ET AL.: "Homo sapiens clone 11-67js mRNA, partial sequence." XP002103205 see the whole document</p> <p>---</p>	44,45, 60,62, 67,70
X	<p>DATABASE EMBL - EMBEST18 Entry MM1140465, Acc.no. AA221749, 15 February 1997 MARRA, M. ET AL.: "my28g01.r1 Barstead mouse pooled organs MPLRB4 Mus musculus cDNA clone 697200 5' similar to TR:E239664 E239664 CHROMOSOME XIV READING FRAME ORF YNL021W." XP002103206 see the whole document</p> <p>---</p>	44,45, 60,62, 67,70
X	<p>NAGASE T ET AL: "PREDICTION OF THE CODING SEQUENCES OF UNIDENTIFIED HUMAN GENES VI. THE CODING SEQUENCES OF 80 NEW GENES (KIAA0201-KIAA0280) DEDUCED BY ANALYSIS OF CDNA CLONES FROM CELL LINE KG-1 AND BRAIN" DNA RESEARCH, vol. 3, no. 5, 1 January 1996, pages 321-329, XP002059454 see the whole document -& DATABASE EMBL - EMHUM1 Entry HSD455, Acc.no. D87455, 9 November 1996 NOMURA, N.: "Human mRNA for KIAA0266 gene, complete cds." XP002103207 see the whole document</p> <p>---</p> <p style="text-align: center;">-/--</p>	44,45, 60,62, 67,70

INTERNATIONAL SEARCH REPORT

International Application No

PCT, 98/14679

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE EMBL - EMBEST16 Entry HSAA51187, Acc.no. AA151187, 15 December 1996 HILLIER, L. ET AL.: "zo03c11.r1 Stratagene colon (#937204) Homo sapiens cDNA clone 566612 5'." XP002103208 see the whole document</p> <p>---</p>	44,45, 60,62, 67,70
X	<p>DATABASE EMBL - EMHUM2 Entry HSU50839, Acc.no. U50839, 9 March 1997 LATIF, F. ET AL.: "Homo sapiens g16 protein (g16) mRNA, complete cds." XP002103209 see the whole document</p> <p>---</p>	44,45, 60,64, 67,70
X	<p>LI, H. ET AL.: "Isolation and sequence analysis of the human syntaxin-encoding gene." GENE, vol. 143, 1994, pages 303-4, XP002103182 see the whole document</p> <p>---</p>	44,45, 47,48, 59,60, 65, 70-72, 74,83,84
X	<p>DATABASE EMBL - EMBEST11 Entry HS1188646, Acc.no. AA285170, 5 April 1997 STRAUSBERG, R.: "zs48f04.s1 NCI CGAP_GCB1 Homo sapiens cDNA clone IMAGE:700735_3'." XP002103210 see the whole document</p> <p>---</p>	44,45, 59,60, 67-70
X	<p>FISHER, D.Z. ET AL.: "cDNA sequencing of nuclear lamins A and C reveals primary and secondary structural homolgy to intermediate filament proteins." PROC.NAT'L.ACAD.SCI.USA, vol. 83, September 1986, pages 6450-4, XP002103184 see figure 2</p> <p>---</p>	44,45, 59,60, 67-70
X	<p>DATABASE EMBL - EMBEST16 Entry HSAA54222, Acc.no. AA454222, 11 June 1997 HILLIER, L. ET AL.: "zx48g12.s1 Soares testis NHT Homo sapiens cDNA clone 795526 3' similar to gb:D42040 RING3 PROTEIN (HUMAN)" XP002103189 see the whole document</p> <p>---</p>	67,69

-/--

INTERNATIONAL SEARCH REPORT

International Application No

PCT, 98/14679

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE EMBL - EMBEST11 Entry HS125289, Acc.no. AA454221, 11 June 1997 HILLIER, L. ET AL.: "zx48g12.r1 Soares testis NHT Homo sapiens cDNA clone 795526 5' similar to TR:E243068 E243068 KINASE." XP002103190 see the whole document</p> <p>---</p>	67,69
X	<p>DATABASE EMBL - EMBEST20 Entry MMAA84412, Acc.no. AA184412, 19 February 1997 MARRA, M. ET AL.: "mt34f07.r1 Soares mouse 3NbMS Mus musculus cDNA clone 622981 5' similar to SW:OXYB HUMAN P22059 OXYSTEROL-BINDING PROTEIN." XP002103194 see the whole document</p> <p>---</p>	67-70
A	<p>WO 96 29409 A (LUDWIG INST CANCER RES ;UNIV LEIDEN (NL)) 26 September 1996</p> <p>see the whole document</p> <p>---</p>	1-11, 17-33, 39-52, 58-61, 67-117
A	<p>WO 92 20356 A (LUDWIG INST CANCER RES) 26 November 1992</p> <p>see the whole document, particularly the claims</p> <p>---</p>	1-11, 17-33, 39-52, 58-61, 67-117
A	<p>WO 95 23874 A (LUDWIG INST CANCER RES) 8 September 1995 see page 5, line 10-14; claims 3,4,7; examples 33,36,43,44</p> <p>---</p>	1-4
A	<p>FRANZÉN, B. ET AL.: "Analysis of polypeptide expression in benign and malignant human breast lesions: down-regulation of cytokeratins." BRITISH JOURNAL OF CANCER, vol. 73, 1996, pages 1632-8, XP002104551 see abstract</p> <p>---</p>	1,2,4-9, 13
A	<p>WO 96 10413 A (LUDWIG INST CANCER RES) 11 April 1996 see the whole document, particularly the claims see abstract</p> <p>---</p> <p style="text-align: center;">-/--</p>	3,19,20, 26,39

INTERNATIONAL SEARCH REPORT

International Application No

PCT, 98/14679

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	BOON T ET AL: "Tumor antigens recognized by T cells" IMMUNOLOGY TODAY, vol. 18, no. 6, June 1997, page 267-268 XP004068293 see the whole document ---	
A	SAHIN, U. ET AL.: "Human neoplasms elicit multiple specific immune responses in the autologous host." PROC.NATL.ACAD.SCI.USA, vol. 92, December 1995, pages 11810-3, XP002091914 cited in the application see the whole document ---	
P,X	DATABASE EMBL - EMHUM1 Entry/Acc.no. AC004022, 22 January 1998 HINDS, K. ET AL.: "Homo sapiens BAC clone GS155M11 from 7q21-q22, complete sequence." XP002091837 from nt.330-810 ---	1,2
P,X	ALAIYA, A.A. ET AL.: "Phenotypic analysis of ovarian carcinoma: polypeptide expression in benign, borderline and malignant tumors." JOURNAL OF CNACER, vol. 73, no. 5, 27 November 1997, pages 678-83, XP002104552 see abstract; figure 2 ---	1-10,15
P,X	GÜRE, A.O. ET AL.: "Human lung cancer antigens recognized by autologous antibodies: definition of a novel cDNA derived from the tumor suppressor gene locus on chromosome 3p21.3" CANCER RESEARCH, vol. 58, 1 March 1998, pages 1034-41, XP002103188 see the whole document ---	1,2,4,5, 9,14,18, 21,22, 27,44, 45,49, 50,55, 59,60, 64, 67-70, 83,84
P,X	SCANLAN, M.J. ET AL.: "Characterization of human colon cancer antigens recognized by autologous antibodies" INTERNATIONAL JOURNAL OF CANCER, 29 May 1998, pages 652-8, XP002103186 see the whole document ---	31,32, 34,40, 59,60, 62, 67-70, 83,84, 116

-/--

INTERNATIONAL SEARCH REPORT

International Application No

PCT, , 98/14679

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	<p>NAGASE, T. ET AL.: "Prediction of the coding sequence of unidentified human genes. IX. The complete sequence of 100 new cDNA clones from barin which can code for large proteins in vivo."</p> <p>DNA RESEARCH, vol. 5, 28 February 1998, pages 31-39, XP002103187 see figure 1; table 3 -& DATABASE EMBL Entry/acc.no. AB011172, 10 April 1998 NAGASE, T. ET AL.: "Homo sapiens mRNA for KIAA0600 protein, partial cds." XP002104556 see the whole document</p>	44,45, 67-70, 83,84
P,X	<p>JONES, M.H. ET AL.: "Identification and characterization of BRDT: a testis-specific gene related to the bromodomain genes RING3 and Drosophila fsh."</p> <p>GENOMICS, vol. 45, no. 3, 1 November 1997, pages 529-34, XP002103185 see page 529, right-hand column, paragraph 2 see page 530, left-hand column, paragraph 2; figure 1 see page 532, right-hand column, paragraph 2</p>	44,45, 59,60, 67-70, 83,84
P,X	<p>ISHIKAWA K ET AL: "Prediction of the coding sequences of unidentified human genes. X The complete sequences of 100 new cDNA clones from brain which can code for large proteins in vitro"</p> <p>DNA RESEARCH, vol. 5, no. 321, 30 June 1998, pages 169-176, XP002089186 see abstract; figures 1,2; table 2</p>	44,59, 60,63, 67-70
E	<p>US 5 858 723 A (MUELLER-LANTZSCH NIKOLAUS ET AL) 12 January 1999</p> <p>Also against claims 108,109,116,117 see the whole document</p>	1,2, 4-10,31, 32,40, 42,43, 49,50, 58-60, 67,69, 71,72, 74-79, 82-84, 99-104

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 98/14679

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages:-	Relevant to claim No.
E	WO 98 40483 A (HUMAN GENOME SCIENCES INC ;GREENE JOHN M (US); LI YI (US); ROSEN C) 17 September 1998 Also against claims 74,76-80,82-85,88,89, 99-104,108,109,111,116,117. See seq. 24 and the claims. ---	1,2, 4-10,14, 18, 21-24, 27,28, 31,32, 36,40, 44,45, 47-50, 55, 58-60, 64,67-72
E	WO 98 08866 A (WISTAR INST) 5 March 1998 see the whole document ---	1,2
E	WO 98 48015 A (CHUGAI RES INST MOLECULAR MED ;JONES MICHAEL H CHUGAI RESEARC (JP)) 29 October 1998 see whole document, particularly the claims. & DATABASE WPI Derwent Publications Ltd., London, GB; AN 98-583658 XP002103211 see abstract ---	18,22, 23, 27-29, 31,32, 40, 44-50, 58-60, 67-72, 74, 76-78, 85,88, 89,102, 103
E	WO 98 32853 A (GENETICS INST) 30 July 1998 see seq. 7 and 8 see page 6, line 23 - page 8, line 12; claims 20-22 see page 21, line 17 - page 22, line 11 ---	18,21, 22,24, 27-29, 44,45, 47-50, 53,59, 60,62, 67-72, 74, 76-80,82

-/--

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 98/14679

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
T	<p>SCANLAN, M.J. ET AL.: "Isoforms of the human PDZ-73 protein exhibit differential tissue expression" BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1445, no. 1, 1999, pages 39-52, XP002104553 also for claims 77-80,82-84,116. see the whole document ---</p>	
T	<p>DRABKIN, H.A. ET AL.: "DEF-3(g16/NY-LU-12), an RNA binding protein from the 3p21.3 homozygous deletion region in SCLC" ONCOGENE, vol. 18, 1999, pages 2589-97, XP002104554 see the whole document -----</p>	

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 98/14679

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 85-111 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☒ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

1-14,17-36,39-55,58-64,67-117; see additional sheets, pages 3-4.
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

Invention 1: claims 1-11,17-33,39-52,58-61,67-117,
all partially

The nucleic acid sequence of Seq.ID 1, fragments or complements thereof, and the corresponding polypeptide(s) encoded thereby, and immunogenic and/or HLA binding fragments thereof, optionally as part of a complex with a HLA molecule, an expression vector comprising said nucleic acid, and optionally a human HLA molecule, a host cell transformed with said vector, and an antibody against said polypeptide(s).

Also a method of diagnosing of a disorder characterised by overexpression of said polypeptide(s) and a method for determining regression, progression or onset of a disease associated with overexpression of said polypeptide(s), using agents that specifically bind to said nucleic acid, said polypeptide(s) or complexes of (fragments of) said polypeptide(s) and a HLA molecule. A kit comprising two polynucleotides for the detection of said nucleic acid
Also pharmaceutical preparations

- which enrich the presence of said polypeptide-HLA complex, optionally comprising an adjuvant, or
- which inhibits the expression of said polypeptide(s), or
- comprising an agent that selectively binds said polypeptide, optionally as a conjugate with a diagnostic or therapeutic compound, or
- comprising said nucleic acid, optionally in an expression vector, optionally in a host cell, or
- comprising said polypeptide(s), optionally in combination with an adjuvant, or
- comprising cytolytic T cells, specific for said polypeptide-HLA complex, or
- comprising an antibody against said polypeptide(s).

Inventions 2-119: claims 1-11,13,15,17-33,35,37,
39-52,54,56,58-61,63,65,67-117, all partially (1)

Inventions 2-119: Idem as subject 1 but limited to each of the DNA sequences as in Seq.ID:2-40,66,89-169 (odd numbers), 170,172,174, and 176-210, where invention 2 is limited to Seq.ID:2 and corresponding polypeptides encoded thereby, invention 3 is limited to Seq.ID:3 and corresponding polypeptides encoded thereby,....., and invention 119 is limited to Seq.ID:210 and corresponding polypeptides encoded thereby.

Invention 120: claims 1-10,13,17-32,35,
39-51,54,58-60,63,67-117, all partially

Idem as subject 1 but limited to the DNA sequences seq.ID:211 and 329 and corresponding polypeptides encoded thereby.

Inventions 121-452: claims 1-10,13,16-32,35,38-51, 54,57-60,63,66-117, all partially (1)

Inventions 121-452: Idem as subject 1 but limited to each of the DNA sequences as in Seq.ID:212-328, and 330-543, where invention 121 is limited to Seq.ID:211 and corresponding polypeptides encoded thereby, invention 122 is limited to Seq.ID:212 and corresponding polypeptides encoded thereby,....., and invention 452 is limited to Seq.ID:543 and corresponding polypeptides encoded thereby.

Invention 453: claims 1-10,12,17-32,34,39-51,53, 58-60,62,67-117, all partially

Idem as subject 1 but limited to the DNA sequences seq.ID:544 and 554 and corresponding polypeptides encoded thereby.

Inventions 454 and 455: claims 1-10,12,17-32,34, 39-51,53,58-60,62,67-117, all partially

Inventions 454 and 455: Idem as subject 1 but limited to each of the DNA sequences as in Seq.ID:546 and 548, where invention 454 is limited to Seq.ID:546 and corresponding polypeptides encoded thereby, and invention 455 is limited to Seq.ID:548 and corresponding polypeptides encoded thereby.

Invention 456: claims 1-10,12,17-32,34,39-51,53, 58-60,62,67-117, all partially

Idem as subject 1 but limited to each of the DNA sequences as in Seq.ID:550, 552, 556, 558 and 560 and corresponding polypeptides encoded thereby.

Inventions 457-582: claims 1-10,12-14,17-32,34-36, 39-51,53-55,58-60,62-64,67-117, all partially (1)

Inventions 457-582: Idem as subject 1 but limited to each of the DNA sequences as in Seq.ID:562-586 (even numbers),

588-683, 686, 687, 689, 691, 692, 692, and 696-706, where invention 457 is limited to Seq.ID:562 and corresponding polypeptides encoded thereby, invention 458 is limited to Seq.ID:564 and corresponding polypeptides encoded thereby,....., and invention 582 is limited to Seq.ID:706 and corresponding polypeptides encoded thereby.

Invention 583: claims 1-10, 14, 17-32, 36, 39-51, 55, 58-60, 64, 67-117, all partially

Idem as subject 1 but limited to each of the DNA sequences as in Seq.ID:707, 709, 711 and 712 and corresponding polypeptides encoded thereby.

Inventions 584-592: claims 1-117, all partially (1)

Inventions 584-592: Idem as subject 1 but limited to each of the DNA sequences as in Seq.ID:799-815 (odd numbers), where invention 584 is limited to Seq.ID:799 and corresponding polypeptides encoded thereby, invention 585 is limited to Seq.ID:801 and corresponding polypeptides encoded thereby,....., and invention 592 is limited to Seq.ID:815 and corresponding polypeptides encoded thereby).

For the sake of conciseness, the subject matter of the first invention is explicitly defined, the other subject matters are defined by analogy thereto.

(1) In as far as the claims searched for a group of inventions refer to specific groups of sequences, only those claims which refer to the groups comprising the nucleic acid sequence of a particular invention, and/or its corresponding polypeptide sequence(s), form parts of that invention.

Due to the fact that extensive sequence homologies were found between several groups of sequences during the additional searches, some of the sequences have been grouped, whereby each of these groups comprising two or more such homologous sequences is considered to be one invention.

Claims searched during primary and additional searches: 1-14, 17-36, 39-55, 58-64, 67-117, limited to:

Invention 1, seq.ID.1
Invention 52, seq.ID.111, and 112 (transl.)
Invention 61, seq.ID.129, and 130 (transl.)
Invention 71, seq.ID.149, and 150 (transl.)
Invention 72, seq.ID.151, and 152 (transl.)
Invention 116, seq.ID.206
Invention 120, seq.ID.211 and 329; (related sequences)
Invention 137, seq.ID.228
Invention 139, seq.ID.330

INVITATION TO PAY ADDITIONAL FEES

International application No.

PCT/US 98/14679

Invention 219, seq.ID.411
Invention 453, seq.ID.544, and 545 (transl.),
and seq.ID.554, and 555 (transl.);
(related sequences)
Invention 454, seq.ID.546, and 547 (transl.)
Invention 455, seq.ID.548, and 548 (transl.)
Invention 456, seq.ID.550, and 551 (transl.),
and seq.ID.552, and 553 (transl.),
and seq.ID.556, and 557 (transl.),
and seq.ID.558, and 559 (transl.),
and seq.ID.560, and 561 (transl.);
(related sequences)
Invention 547 seq.ID.665
Invention 548, seq.ID.666
Invention 554, seq.ID.672
Invention 558, seq.ID.676
Invention 563, seq.ID.681
Invention 566, seq.ID.686
Invention 583, seq.ID.707, and 708 (transl.),
and seq.ID.709, and 710 (transl.),
and seq.ID.711,
and seq.ID.712;
(related sequences).

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT, JS 98/14679

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9717470 A	15-05-1997	US 5686247 A AU 1271497 A EP 0866878 A	11-11-1997 29-05-1997 30-09-1998
GB 2273099 A	08-06-1994	WO 9411514 A	26-05-1994
WO 9717441 A	15-05-1997	AU 7505696 A EP 0869176 A	29-05-1997 07-10-1998
WO 9702362 A	23-01-1997	US 5716782 A AU 6393196 A CA 2222371 A EP 0835326 A	10-02-1998 05-02-1997 23-01-1997 15-04-1998
WO 9615149 A	23-05-1996	US 5623051 A AU 4282396 A CA 2206110 A EP 0791013 A JP 10509945 T	22-04-1997 06-06-1996 23-05-1996 27-08-1997 29-09-1998
WO 9721729 A	19-06-1997	AU 1331797 A	03-07-1997
WO 9629409 A	26-09-1996	AU 5429896 A CA 2211448 A EP 0815229 A ZA 9602280 A	08-10-1996 26-09-1996 07-01-1998 28-08-1996
WO 9220356 A	26-11-1992	US 5342774 A AU 664560 B AU 2158392 A CA 2109727 A EP 0595838 A FI 935174 A JP 6511144 T NO 934130 A PT 100515 A US 5541104 A US 5612201 A US 5843448 A	30-08-1994 23-11-1995 30-12-1992 26-11-1992 11-05-1994 22-11-1993 15-12-1994 23-11-1993 31-08-1993 30-07-1996 18-03-1997 01-12-1994
WO 9523874 A	08-09-1995	US 5512437 A US 5763165 A US 5612201 A US 5512444 A AU 698310 B AU 1968295 A CA 2184482 A EP 0871765 A FI 963393 A JP 9509832 T NO 963589 A NZ 282536 A US 5763155 A	30-04-1996 09-06-1998 18-03-1997 30-04-1996 29-10-1998 18-09-1995 08-09-1995 21-10-1998 30-08-1996 07-10-1997 31-10-1996 28-07-1996 09-06-1998
WO 9610413 A	11-04-1996	AU 690371 B AU 3886495 A CA 2201327 A CN 1159759 A	23-04-1998 26-04-1996 11-04-1996 17-09-1997

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT, JS 98/14679

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9610413 A		EP 0782453 A	09-07-1997
		JP 10511639 T	10-11-1998
		ZA 9508229 A	24-04-1996
US 5858723 A	12-01-1999	NONE	
WO 9840483 A	17-09-1998	AU 6552198 A	29-09-1998
		WO 9854963 A	10-12-1998
WO 9808866 A	05-03-1998	US 5858005 A	12-01-1999
		AU 4171797 A	19-03-1998
		WO 9910036 A	04-03-1999
WO 9848015 A	29-10-1998	AU 6853998 A	13-11-1998
WO 9832853 A	30-07-1998	AU 5828398 A	18-08-1998